On August 31, 2021, the U.S. Food and Drug Administration (FDA) approved a supplemental application for Keytruda (pembrolizumab). This approval, categorized as an efficacy supplement, was granted to sponsor MERCK SHARP DOHME.
Background
Pembrolizumab (Keytruda) is a well-known immunotherapy drug that has received multiple prior approvals for various cancer indications. The FDA's approval of a supplemental application for Keytruda on August 31, 2021, specifically for efficacy, indicates an expansion or modification related to its established therapeutic profile. This type of supplemental approval typically arises from new clinical data supporting additional benefits or uses for the drug, allowing for updates to the official prescribing information.
What this means
A supplemental FDA approval for efficacy is a significant regulatory action. It typically signifies that a drug's official label has been updated to include new information about its effectiveness, which can be crucial for guiding clinical practice. This could involve an expanded indication, approval for a new patient population, or updated efficacy data for an existing indication, all based on new clinical trial results. For Keytruda (pembrolizumab), this specific efficacy approval means that its established therapeutic benefits have been further substantiated or broadened, providing clinicians with additional, officially recognized guidance on its appropriate use. This allows healthcare providers to consider pembrolizumab in potentially new or refined clinical contexts, impacting treatment strategies for patients and potentially improving outcomes.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 125514 S-118 was documented on August 31, 2021, on accessdata.fda.gov.